In addition, since CBX3 has been linked to epigenetic changes such as H3K9me3, which plays a role in regulating the response to DNA damage, we speculate that it could potentially contribute to the resistance of tumor-initiating cells in NSCLC to antineoplastic drugs. This evidence concerns the gene CBX3 and non-small cell lung carcinoma.